Most of what I read about fatty liver treats it as a liver problem, full stop. Cut the alcohol, cut the sugar, maybe add milk thistle, and hope the liver heals itself. A new study out of Michigan Medicine makes the case that for at least one severe form of fatty liver disease, the actual problem might be starting somewhere else entirely, in the gut.
Researchers tested an experimental tripeptide drug candidate called DT 109 in mice and nonhuman primates with metabolic dysfunction associated steatohepatitis, or MASH, a severe and progressive form of fatty liver disease. Instead of targeting the liver, DT 109 went after a specific gut bacterium, Clostridium perfringens, that overgrows in MASH and produces excess ammonia. That ammonia damages the intestinal lining, and once that barrier is compromised, bacterial toxins travel straight to the liver through the portal vein, driving the inflammation and fibrosis that define the disease.
In both mice and nonhuman primates, DT 109 suppressed Clostridium perfringens growth, cut ammonia production, strengthened the gut barrier, and reduced liver inflammation and MASH severity. The primate data matters more than usual here, since primate gut microbiota and liver physiology track much closer to human biology than mouse models do. The same compound has separately shown effects on limiting arterial plaque and calcification in primates too, which points to one mechanism with reach beyond just the liver. The study was published in the Journal of Clinical Investigation on July 1, 2026, with Michigan Medicine and ScienceDaily both covering the same findings.
DT 109 is a drug candidate, not a supplement, and it is not available to anyone right now. Every result here comes from mice and nonhuman primates. There is no human trial data yet, and this is the first study to show this exact mechanism, so it has not been independently replicated. Nothing here validates any existing probiotic, gut health supplement, or liver support product. The mechanism is specific to this one compound targeting this one bacterium, not a general case for taking a probiotic to protect your liver.
You cannot buy DT 109 and there is nothing actionable to do with it yet. What is genuinely useful here is the reframe. If gut barrier damage can drive a serious liver disease in animal models, it is a real reason to treat gut health and liver health as connected rather than separate concerns, and a reason to be skeptical of any liver detox product that only claims to work on the liver itself. I will be watching for human trial data on this mechanism, and for any independent lab that replicates the Clostridium perfringens connection.
DT 109 is an experimental tripeptide drug candidate tested so far only in mice and nonhuman primates. It is not an approved medication and it is not sold as a supplement, so there is no human safety or dosing data yet, and nothing about buying or taking it right now.
No. This study tested one experimental drug candidate against one specific gut bacterium, Clostridium perfringens, and its ammonia output. It does not test or validate any existing probiotic, prebiotic, or liver support supplement on the market. The honest takeaway is a mechanism worth watching, not a product recommendation.
The gut and liver share a direct blood supply through the portal vein. When the intestinal lining is damaged, bacterial byproducts like ammonia and toxins can travel straight to the liver and drive inflammation there. Researchers call this the gut liver axis, and it is why gut barrier health and liver health are increasingly treated as one connected system rather than two separate problems.
Get the Daily Signal in your inbox each morning, verified and no hype, before you even open your phone.